Investor Presentaiton

Generic API Division 317 Anti Viral API 214 273 336 379 60 60 Onco API 47 47 59 51 86 Other API 98 90 92 Cr 135 106 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 • Anti Viral API revenue showed a growth of 20% (YoY) Onco API revenue showed a growth of 43% (YoY) Other API revenue showed a growth of 18% (YoY) Q2 FY 21 Contribution 19% ■ Anti Viral 15% ■ Onco 66% ■ Others 6 LAURUS Labs Knowledge Innovation. Excelence

View entire presentation